natgillin/translations-raw huggingface dataset:
Hulio treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of conditions for which Hulio is indicated. 
Zdravljenje z zdravilom Hulio mora uvesti in nadzorovati zdravnik specialist, izkušen v diagnosticiranju in zdravljenju bolezni, za katere je zdravilo Hulio indicirano.
Of the 417 subjects included in the uncontrolled long-term extension of Studies UV I and UV II, 46 subjects were regarded ineligible (e.g. developed complications secondary to diabetic retinopathy, due to cataract surgery or vitrectomy) and were excluded from the primary analysis of efficacy. 
Od 417 bolnikov, ki so bili vključeni v nekontrolirano podaljšano študijo UV I in UV II, je bilo 46 bolnikov neprimernih (npr. razvili so se zapleti, sekundarno ob diabetični retinopatiji zaradi operacije sive mrene ali vitrektomije) in so bili izključeni iz primarne analize učinkovitosti.
73% of patients enrolled in Psoriasis Studies I and II had received prior systemic therapy or phototherapy. 
73 % bolnikov, vključenih v študiji psoriaze I in II, je predhodno dobivalo sistemsko zdravljenje ali fototerapijo.
Wipe the skin at the chosen injection site with a new alcohol swab. 
Očistite kožo na izbranem injekcijskem mestu z novim alkoholnim zložencem.
b Patients meeting protocol-specified criteria for loss of response or no improvement were required to discontinue from the studies and were counted as nonresponders. 
b Bolniki, ki izpolnjujejo merila, določena v protokolu, za izgubo odziva ali brez izboljšanja, so bili izključeni iz študij in so jih šteli kot bolnike brez odziva (»nonresponders«).
In the Viewing Window, the Orange Indicator will advance to show the progress of the injection. 
V kontrolnem okencu boste videli pomikanje oranžnega kazalnika, ki kaže napredek injiciranja.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you. 
Natančno preberite to navodilo, preden vaš otrok začne uporabljati to zdravilo, ker vsebuje pomembne podatke zanj.
Reduction in HS-related skin pain was assessed using a Numeric Rating Scale in patients who entered the study with an initial baseline score of 3 or greater on a 11 point scale. 
Zmanjšanje bolečine kože, povezane s HS, so ocenili s pomočjo numerične ocenjevalne lestvice pri bolnikih, ki so imeli pri vključitvi v študijo izhodiščni rezultat 3 ali več na 11-stopenjski numerični ocenjevalni lestvici.
Ophthalmologists are advised to consult with an appropriate specialist before initiation of treatment with Hulio (see section 4.4). 
Oftalmologom se svetuje, da se pred začetkom zdravljenja z zdravilom Hulio posvetujejo z ustreznim specialistom (glejte poglavje 4.4).
Seek medical attention urgently if you develop any of the following signs of allergic reaction or heart failure: 
Nemudoma poiščite zdravniško pomoč, če se pojavijo kateri koli od naslednjih znakov alergijske reakcije ali srčnega popuščanja:
Patients may first be given other medicines. 
Bolniki bodo morda najprej prejeli druga zdravila.
Other medicines and Hulio 
Druga zdravila in zdravilo Hulio
Firmly push the body of the pen down against the injection site to engage the Orange Activator and begin the injection. 
Injekcijski peresnik čvrsto potisnite navzdol proti injekcijskemu mestu, da aktivirate oranžni aktivator in začnete z injiciranjem.
Find a quiet area with a well-lit, clean and flat work surface and gather all the supplies you will need to give yourself or receive the injection. 
Poiščite miren kraj z dobro osvetljeno, čisto in ravno delovno površino ter pripravite vse pripomočke, ki jih boste potrebovali, da si daste ali vam dajo injekcijo.
Side effects may occur up to 4 months or more after the last Hulio injection. 
Neželeni učinki se lahko pojavijo do 4 mesece po zadnji injekciji zdravila Hulio ali kasneje.
Improvement in health-related quality of life and physical function was maintained during the open-label extension through week 156. 
Izboljšanje z zdravjem povezane kakovosti življenja in telesne funkcije se je pri odprtih podaljšanjih študij ohranjalo do 156. tedna.
Solution for injection Multipack: 2 packs of 1 vial each. 
raztopina za injiciranje Večkratno pakiranje: 2 pakiranji s po 1 vialo.
Supplies you will need: 
Potrebujete naslednje pripomočke:
DO NOT pull the white plunger rod completely out of the syringe. 
NE POTEGNITE belega nosilca bata popolnoma iz brizge.
Hulio contains the active substance adalimumab, a medicine that acts on your body's immune (defence) system. 
Zdravilo Hulio vsebuje učinkovino adalimumab, zdravilo, ki učinkuje na imunski (obrambni) sistem telesa.
The target of adalimumab is another protein called tumour necrosis factor (TNFα), which is present at increased levels in the inflammatory diseases listed above. 
Tarča adalimumaba je beljakovina, ki se imenuje tumorje nekrotizirajoči faktor (TNFα) in je prisotna v povečanih koncentracijah pri zgoraj navedenih vnetnih boleznih.
If active tuberculosis is diagnosed, Hulio therapy must not be initiated (see section 4.3). 
Če se odkrije aktivna tuberkuloza, se zdravljenja z zdravilom Hulio ne sme začeti (glejte poglavje 4.3).
If you do not have all the supplies you need, ask your nurse or pharmacist. 
Če nimate vseh pripomočkov, ki jih potrebujete, zanje prosite medicinsko sestro ali farmacevta.
Do not mix any other medicine into the same syringe or vial with the Hulio solution. 
Ne mešajte nobenega drugega zdravila v isti injekcijski brizgi ali viali z raztopino zdravila Hulio.
• 2 alcohol pads (4) 
• 2 alkoholna zloženca (4);
Treatment with Hulio should not be initiated in patients with active infections including chronic or localised infections until infections are controlled. 
Zdravljenja z zdravilom Hulio se ne sme začeti pri bolnikih z aktivnimi okužbami, vključno s kroničnimi ali lokaliziranimi, dokler te niso obvladane.
• DO NOT recycle your used sharps disposal container. 
• Uporabljenega vsebnika za odlaganje ostrih predmetov NE RECIKLIRAJTE.
Adalimumab /MTX n=268 (95% confidence interval) 
adalimumab/MTX n = 268 (95-% interval zaupanja)
Some patients who have been successfully treated for active tuberculosis have redeveloped tuberculosis while being treated with adalimumab. 
Nekaterim bolnikom, ki so bili uspešno zdravljeni zaradi aktivne tuberkuloze, se je med zdravljenjem z adalimumabom ponovno razvila tuberkuloza.
Some of those patients were also treated with the medicines azathioprine or mercaptopurine. 
Nekateri od teh bolnikov so bili zdravljeni tudi z azatioprinom ali merkaptopurinom.
Study nr-axSpA II was a treatment withdrawal study in nr-axSpA patients who achieved remission during open-label treatment with adalimumab. 
Študija nr-axSpA II je bila študija prenehanja zdravljenja pri bolnikih z nr-axSpA, ki so med zdravljenjem z adalimumabom v odprti fazi zdravljenja dosegli remisijo.
Use of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Hulio in patients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. 
O uporabi protituberkuloznega profilaktičnega zdravljenja morate pred uvedbo zdravila Hulio razmisliti tudi pri bolnikih s hudimi ali pomembnimi faktorji tveganja za tuberkulozo kljub negativnemu testu za tuberkulozo in pri bolnikih z anamnezo latentne ali aktivne tuberkuloze, pri katerih ni mogoče potrditi ustreznega zdravljenja.
fungal infections, joint infections); 
glivičnimi okužbami, okužbami sklepov);
Similar trends (not all statistically significant) were seen in the smaller randomised, double − blind, placebo controlled AS study II of 82 adult patients with active ankylosing spondylitis. 
Podobni trendi (ki pa niso bili vsi statistično značilni) so bili opazni v manjši, randomizirani, dvojno slepi, s placebom kontrolirani študiji ankilozirajočega spondilitisa II pri 82 odraslih bolnikih z aktivnim ankilozirajočim spondilitisom.
Of the 371 remaining patients, 276 evaluable patients reached 78 weeks of open-label adalimumab treatment. 
Od preostalih 371 bolnikov je 276 za oceno primernih bolnikov zaključilo 78-tedensko odprto zdravljenje z adalimumabom.
Population pharmacokinetic analyses with data from over 1,300 RA patients revealed a trend toward higher apparent clearance of adalimumab with increasing body weight. 
Analize populacijske farmakokinetike s podatki za več kot 1300 bolnikov z revmatoidnim artritisom so pokazale trend k večjemu navideznemu očistku adalimumaba z večanjem telesne mase.
The combination of Hulio and anakinra or abatacept is not recommended based upon the possible increased risk for infections, including serious infections and other potential pharmacological interactions. 
Kombinacija zdravila Hulio in anakinre ali abatacepta ni priporočljiva zaradi možnega povečanega tveganja za okužbe, vključno z resnimi okužbami, in drugih potencialnih farmakoloških interakcij.
Slowly push the plunger completely down until all the medicine is injected and the syringe is empty. 
Počasi potisnite bat do konca, dokler ne injicirate vsega zdravila in je injekcijska brizga prazna.
If latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis treatment before the initiation of Hulio, and in accordance with local recommendations. 
Če ugotovite latentno tuberkulozo, morate pred uvedbo zdravila Hulio začeti s protituberkuloznim profilaktičnim zdravljenjem v skladu z lokalnimi priporočili.
Thus, additional caution should be exercised in considering adalimumab treatment of these patients (see section 4.8). 
Torej je potrebna dodatna previdnost, kadar razmišljamo o zdravljenju z adalimumabom pri teh bolnikih (glejte poglavje 4.8).
In patients who develop HBV reactivation, Hulio should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated. 
Pri bolnikih, pri katerih se pojavi reaktivacija HBV, je treba uporabo zdravila Hulio prekiniti in uvesti učinkovito protivirusno terapijo z ustreznim podpornim zdravljenjem.
Patients treated with Hulio should be given the Patient Reminder Card. 
Bolniki, ki se zdravijo z zdravilom Hulio, morajo dobiti opozorilno kartico za bolnike.
The primary efficacy endpoint in both studies was ´time to treatment failure´. 
Primarni opazovani dogodek kot merilo učinkovitosti je bil v obeh študijah »čas do neuspeha zdravljenja«.
The decision to stop using Hulio should be discussed with your doctor. 
O odločitvi, da bi prenehali uporabljati zdravilo Hulio, se morate posvetovati s svojim zdravnikom.
Find a quiet area with a well-lit, clean and flat work surface and gather all the supplies you will need to give the injection. 
Poiščite miren kraj z dobro osvetljeno, čisto in ravno delovno površino ter pripravite vse pripomočke, ki jih boste potrebovali za injiciranje.
Also contains: monosodium glutumate, sorbitol (E420), methionine, polysorbate 80, hydrochloric acid and water for injections. 
Vsebuje tudi: mononatrijev glutamat, sorbitol (E420), metionin, polisorbat 80, klorovodikovo kislino in vodo za injekcije.
• 1 needle (5) 
• 1 iglo (5).
In a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn's disease (CD) treated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with adalimumab were enrolled. 
V predvidenem kohortnem registru je bilo vključenih 257 žensk z revmatoidnim artritisom (RA) ali Chronovo boleznijo (CB), zdravljenih z adalimumabom vsaj v prvem trimesečju nosečnosti, in 120 žensk z RA ali CB, ki niso bile zdravljene z adalimumabom.
Hulio contains sodium and sorbitol 
Zdravilo Hulio vsebuje natrij in sorbitol.
BCVA was either improved or maintained (< 5 letters deterioration) in 88.4% of the eyes at week 78. 
Najbolje korigirana ostrina vida se je ali izboljšala ali pa ohranila (poslabšanje ostrine vida < 5 črk) pri 88,4 % očeh v 78. tednu.
• 1 vial of Hulio solution (3) 
• 1 vialo z raztopino zdravila Hulio (3);
Roll back any clothing that may interfere with the injection site. 
Umaknite vsa oblačila, ki bi lahko ovirala dostop do injekcijskega mesta.
The active ingredient in Hulio, adalimumab, is a monoclonal antibody. 
Učinkovina v zdravilu Hulio, adalimumab, je monoklonsko protitelo.
Chronic non-infectious uveitis affecting the front of the eye 
Kronični neinfekcijski uveitis, ki prizadene sprednji del očesa
• acidity/acid reflux; 
• hiperacidnost/refluks kisline;
Vision related effects were not numerically in favour of adalimumab for colour vision in Study UVI and for colour vision, peripheral vision and near vision in Study UV II. 
Učinki, povezani z vidom, niso bili v korist adalimumaba v primeru barvnega vida v študiji UV I in v primeru barvnega vida, perifernega vida in vida na blizu v študiji UV II.
In non-infectious uveitis, corticosteroids or other medicines that influence the immune system may be continued while using Hulio. 
V primeru neinfekcijskega uveitisa se kortikosteroidi ali druga zdravila, ki zavirajo imunski sistem, lahko še nadalje uporabljajo ob uporabi zdravila Hulio.
Among patients who had failed prior anti-TNF treatment, week 52 remission was achieved by 3% on placebo and 10% on adalimumab. 
Med bolniki, pri katerih predhodno zdravljenje anti-TNF ni bilo uspešno, jih je 52. teden doseglo remisijo 3 % na placebu in 10 % na adalimumabu.
• worsening skin rash with muscle weakness. 
• poslabšanje kožnega izpuščaja, ki ga spremlja mišična šibkost.
Step 2 - Wash hands 
2. korak - Umijte si roki.
INFORMATION IN BRAILLE Hulio 40 mg 
PODATKI V BRAILLOVI PISAVI Hulio 40 mg
Pull the syringe away from the injection site at the same angle as inserted and release your thumb from the plunger. 
Injekcijsko brizgo izvlecite iz injekcijskega mesta pod enakim kotom, kot ste jo vstavili, in umaknite palec z bata.
The proportions of subjects with PedACR50/70/90 at week 12 and week 24 were 90.3%/61.3%/38.7% and 83.3%/73.3%/36.7%, respectively. 
Deleži preiskovancev s Ped ACR 50/70/90 so bili 12. teden 90,3 %/61,3 %/38,7 % in 24. teden 83,3 %/73,3 %/36,7 %.
A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Hulio cannot be excluded (see section 4.8). 
Tveganja za razvoj hepatospleničnega limfoma celic T pri bolnikih, ki prejemajo zdravilo Hulio, ni mogoče izključiti (glejte poglavje 4.8).
Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including adalimumab, who are chronic carriers of this virus (i.e. surface antigen positive). 
Reaktivacijo hepatitisa B so opažali pri bolnikih, ki so prejemali antagonist TNF, vključno z adalimumabom, in ki so bili kronični nosilci tega virusa (tj. pozitivni na površinski antigen).
All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course. 
Vse bolnike z ulceroznim kolitisom, ki imajo večje tveganje za displazijo ali karcinom kolona (npr. bolnike z dolgotrajnim ulceroznim kolitisom ali primarnim sklerozirajočim holangitisom) ali imajo anamnezo displazije ali karcinoma kolona, je treba pred zdravljenjem in redno med potekom bolezni presejalno pregledovati glede displazije.
Improved physical function continued during the open label extension up to week 136. 
Izboljšanje telesnega delovanja je trajalo še med odprtim podaljšanjem do 136. tedna.
Check with your healthcare provider for instructions on how to properly dispose of a filled sharps container. 
Zdravstvenega delavca prosite za navodila, kako pravilno zavreči poln vsebnik za ostre predmete.
Hold the syringe at eye-level with the needle pointing up to see the amount of solution clearly. 
Držite brizgo na ravni oči in z iglo obrnjeno navzgor, da boste jasno videli količino raztopine.
These infections have not consistently been recognised in patients taking TNFantagonists and this has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes. 
Takšne okužbe pri uporabnikih antagonistov TNF niso bile dosledno prepoznane, zato je v primerih njihovega nastanka prihajalo do zamud pri ustreznem zdravljenju, kar je včasih povzročilo smrt.
It is very important that you tell your doctor if you have ever had tuberculosis, or if you have been in close contact with someone who has had tuberculosis. 
Zelo pomembno je, da zdravniku poveste, če ste kadar koli imeli tuberkulozo ali ste bili v tesnem stiku s kom, ki jo je imel.
You should record the date when the syringe is first removed from refrigerator, and the date after which it should be discarded. 
Zapisati si morate datum, ko je bila brizga prvič vzeta iz hladilnika, in datum, po katerem jo je treba zavreči.
• DO NOT touch the top of the syringe. 
• NE DOTIKAJTE se zgornjega dela brizge.
- The other ingredients are monosodium glutumate, sorbitol, methionine, polysorbate 80, 
- Druge sestavine zdravila so mononatrijev glutamat, sorbitol, metionin, polisorbat 80,
Results from the Short Form Health Survey (SF 36) for all doses/schedules of adalimumab in all four studies support these findings, with statistically significant physical component summary (PCS) scores, as well as statistically significant pain and vitality domain scores for the 40 mg every other week dose. 
Te izsledke podpirajo rezultati SF-36 (Short Form Health Survey) za vse odmerke/sheme adalimumaba v vseh štirih študijah, s statistično značilnim seštevkom PCS (Physical Component Summary) in statistično značilnima seštevkoma za področje bolečin in vitalnosti za odmerek 40 mg vsak drugi teden.
Should treatment be interrupted, Hulio may be re-introduced as appropriate. 
Če je treba zdravljenje prekiniti, je možno zdravljenje z zdravilom Hulio znova uvesti, kakor je primerno.
• swollen face, hands or feet; 
• oteklost obraza, dlani ali stopal;
• Tell your doctor if you are a carrier of the hepatitis B virus (HBV), if you have active HBV infection or if you think you might be at risk of contracting HBV. 
• Zdravniku povejte, če ste nosilec virusa hepatitisa B (HBV), če imate aktivno okužbo s HBV ali če mislite, da bi se lahko nalezli HBV.
If an anaphylactic reaction or other serious allergic reaction occurs, administration of Hulio should be discontinued immediately and appropriate therapy initiated. 
Če se pojavi anafilaktična reakcija ali kakšna druga resna alergijska reakcija, je treba uporabo zdravila Hulio nemudoma prekiniti in uvesti ustrezno zdravljenje.
RA studies III and V had an additional primary endpoint at 52 weeks of retardation of disease progression (as detected by X-ray results). 
V študijah revmatoidnega artritisa III in V je bila dodatna primarna končna točka po 52 tednih upočasnitev napredovanja bolezni (ugotovljena z izvidi rentgenskega slikanja).
• Tell your doctor if you have a history of recurrent infections or other conditions that increase the risk of infections. 
• Zdravniku povejte, če ste imeli v preteklosti ponavljajoče se okužbe ali druga stanja, ki povečujejo tveganje za okužbe.
No clinical data are available on the use of a Hulio loading dose in children < 6 years of age (see section 5.2). 
Klinični podatki o uporabi polnilnega odmerka zdravila Hulio pri otrocih, mlajših od 6 let, niso na voljo (glejte poglavje 5.2).
The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience and are displayed by system organ class and frequency in Table 6 below: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); and not known (cannot be estimated from the available data). 
Naslednji seznam neželenih učinkov temelji na izkušnjah iz kliničnih preskušanj in iz obdobja trženja zdravila in jih razvršča po organskih sistemih in pogostnosti v spodnji preglednici 6: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000) in neznana pogostnost (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti).
Adalimumab was numerically favoured for the majority of subscores with statistically significant mean differences for general vision, ocular pain, near vision, mental health, and total score in Study UV I, and for general vision and mental health in Study UV II. 
Številke so bile v korist adalimumaba za večino podrezultatov s statistično značilno povprečno razliko za splošni vid, očesno bolečino, vid na blizu, duševno zdravje in skupen rezultat v študiji UV I ter za splošni vid in duševno zdravje v študiji UV II.
What Hulio looks like and contents of the pack 
Izgled zdravila Hulio in vsebina pakiranja
- If you have a severe infection, including tuberculosis (see “Warnings and precautions”). 
- če imate hudo okužbo, vključno s tuberkulozo (glejte ''Opozorila in previdnostni ukrepi'').
You should record the date when the pen is first removed from refrigerator, and the date after which it should be discarded. 
Zapisati si morate datum, ko je bil peresnik prvič vzet iz hladilnika, in datum, po katerem ga je treba zavreči.
PASI 75 and PGA clear or minimal increased with increasing adalimumab concentrations, both with a similar apparent EC50 of approximately 4.5 μg/ml (95% CI 0.4-47.6 and 1.9-10.5, respectively). 
PASI 75 in PGA čisto ali minimalno sta se povečevali z zvečanjem koncentracije adalimumaba, obe s podobno navidezno EC50, za približno 4,5 µg/ml (95 % IZ 0,4-47,6 in 1,9-10,5).
These infections may be serious and include tuberculosis, infections caused by viruses, fungi, parasites or bacteria, or other unusual infectious organisms and sepsis (blood poisoning). 
Te okužbe so lahko resne in vključujejo tuberkulozo, okužbe, ki jih povzročijo virusi, glive, paraziti ali bakterije, ali druge neobičajne okužbe in sepso (zastrupitev krvi).
Treatment with adalimumab 40 mg every week significantly reduced the risk of worsening of abscesses and draining fistulas. 
Zdravljenje z adalimumabom 40 mg vsak teden statistično pomembno zmanjša tveganje za poslabšanje abscesov in fistul z izcedkom.
Figure 2: Kaplan-Meier Curves Summarizing Time to Treatment Failure on or after week 6 (Study UV I) or week 2 (Study UV II) 
Slika 2: Kaplan-Meierjeve krivulje povzemajo čas do neuspeha zdravljenja v ali po 6. tednu (študija UV I) ali 2. tednu (študija UV II)
Do not mix the Hulio solution with any other medicine. 
Raztopine zdravila Hulio ne mešajte z drugimi zdravili.
In some rare cases, especially if your child is taking other medicines that suppress the immune system, reactivation of HBV infection can be life-threatening. 
V nekaterih redkih primerih, zlasti če vaš otrok uporablja druga zdravila, ki zavirajo imunski sistem, je reaktivacija okužbe s HBV lahko življenjsko ogrožujoča.
Hulio can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. 
Zdravilo Hulio je mogoče uporabiti kot monoterapijo v primeru intolerance za metotreksat ali kadar nadaljnje zdravljenje z metotreksatom ni primerno.
In addition, no malignancies were observed in 192 paediatric patients with an exposure of 498.1 patient years during adalimumab trials in paediatric patients with Crohn's disease. 
Poleg tega niso opazili nobenega malignoma niti pri 192 pediatričnih bolnikih, ki so bili izpostavljeni 498,1 bolnikovlet med študijami z adalimumabom pri pediatričnih bolnikih s Crohnovo boleznijo.
This will include a thorough medical evaluation including your medical history and screening tests (for example chest X-ray and a tuberculin test). 
To bo vključevalo natančno zdravniško oceno, vključno s poizvedbo o zdravju v preteklosti, in preiskave (npr. rentgensko slikanje prsnega koša in tuberkulinski test).
Hulio may have a minor influence on the ability to drive and use machines. 
Zdravilo Hulio ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev.
Step 1 - Choose and prepare injection site 
1. korak - Izberite in pripravite injekcijsko mesto.
Orange Activator (Needle Inside) 
Oranžni aktivator (z iglo)